Leading Neurosurgical Center in Moscow Purchases CyberKnife System to Expand Ability...

Thu Aug 7, 2008 8:31am EDT

* Reuters is not responsible for the content in this press release.

Leading Neurosurgical Center in Moscow Purchases CyberKnife System to Expand
Ability to Treat Brain and Spinal Tumors
Installation at Burdenko Institute of Neurosurgery will be Accuray's Second in

SUNNYVALE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Accuray Incorporated
(Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today
that the Burdenko Institute of Neurosurgery in Moscow has purchased a
CyberKnife(R) Robotic Radiosurgery System.  When the system is installed, the
Burdenko Institute will become the second facility in Russia to offer advanced
robotic radiosurgery treatments.
    The CyberKnife System will enable the Burdenko Institute to expand its
ability to treat tumors and other diseases of the brain and spine.  With
real-time image guidance and the ability to adjust for patient and tumor
movement during treatment, clinicians are able to deliver radiation with
extreme precision without requiring patients to be positioned in uncomfortable
frames.  Because it is non-invasive and does not require the use of frames,
the CyberKnife System is ideal for those users who wish to deliver
fractionated intracranial treatments.
    "The Burdenko Institute is world renowned for its expertise in the
treatment of neurological conditions," said Eric P. Lindquist, senior vice
president and chief marketing officer of Accuray Incorporated.  "With the
addition of a CyberKnife System, clinicians there will be able to expand their
radiosurgical capabilities, while offering patients a viable, non-invasive
alternative to traditional surgery."
    Established in 1932 as the Moscow Institute of Neurosurgery the facility
focused specifically on neurosurgery.  The institute was later renamed for
Nikolai Nilovich Burdenko, who is regarded as the founder of Russian
neurosurgery.  The Burdenko Institute currently is led by Alexander N.
Konovalov, M.D., Ph.D., who has served as its director for more than 32 years
and is one of the foremost figures in Russian neurosurgery.
    The Burdenko Institute will receive its CyberKnife System by the end of
the 2008 calendar year through local distributor Newstep Ltd.
    About the CyberKnife(R) Robotic Radiosurgery System
    The CyberKnife Robotic Radiosurgery System is the world's only robotic
radiosurgery system designed to treat tumors anywhere in the body
non-invasively.  Using continual image guidance technology and computer
controlled robotic mobility, the CyberKnife System automatically tracks,
detects and corrects for tumor and patient movement in real-time throughout
the treatment.  This enables the CyberKnife System to deliver high-dose
radiation with pinpoint precision, which minimizes damage to surrounding
healthy tissue and eliminates the need for invasive head or body stabilization
    About Accuray
    Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a
global leader in the field of radiosurgery dedicated to providing an improved
quality of life and a non-surgical treatment option for those diagnosed with
cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery
System, which extends the benefits of radiosurgery to include extracranial
tumors, including those in the spine, lung, prostate, liver and pancreas.  To
date, the CyberKnife System has been used to treat more than 40,000 patients
worldwide and currently more than 130 systems have been installed in leading
hospitals in the Americas, Europe and Asia.  For more information, please
visit www.accuray.com.
    Safe Harbor Statement
    The foregoing may contain certain forward-looking statements that involve
risks and uncertainties, including uncertainties associated with the medical
device industry.  Except for the historical information contained herein, the
matters set forth in this press release relating to clinical studies,
regulatory review and approval, and commercialization of products are
forward-looking statements within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements speak only as of the date the statements are made and are based on
information available at the time those statements are made and/or
management's good faith belief as of that time with respect to future events.
You should not put undue reliance on any forward-looking statements. Important
factors that could cause actual performance and results to differ materially
from the forward-looking statements we make include: market acceptance of
products; competing products, the combination of our products with
complementary technology; and other risks detailed from time to time under the
heading "Risk Factors" in our report on Form 10-K for the year ended June 30,
2007 as updated from time to time by our quarterly reports on Form 10-Q and
our other filings with the Securities and Exchange Commission. The Company's
actual results of operations may differ significantly from those contemplated
by such forward-looking statements as a result of these and other factors. We
assume no obligation to update forward-looking statements to reflect actual
performance or results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent required by
applicable securities laws.
SOURCE  Accuray Incorporated

Susan Lehman of Rockpoint Public Relations, +1-510-832-6006,
susan@rockpointpr.com, for Accuray; or Stephanie Tomei, Public Relations
Manager of Accuray Incorporated, +1-408-789-4234, stomei@accuray.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.